China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 31 March 2024, the Group through a wholly-owned subsidiary of the Company– a dermatology medical aesthetic company (“CMS Skinhealth”) entered into a Collaboration and License Agreement (the “License Agreement”) with Incyte (NASDAQ:INCY) (“Incyte”), a global biopharmaceutical company, for selective oral smallmolecule JAK1 inhibitor povorcitinib (the “Product”) for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN) and asthma and chronic spontaneous urticaria.
China Medical System Announced Collaboration And License Agreement With Incyte For Selective Oral Smallmolecule JAK1 Inhibitor Povorcitinib
Company Profile
Mon. 1 Apr 2024, 6:40am ET
Benzinga
News